Scott L. Friedman

Interleukin-6 protects hepatocytes from CCl4-mediated necrosis and apoptosis in mice by reducing MMP-2 expression.

Lhx2-/- mice develop liver fibrosis.

Mac the knife? Macrophages- the double-edged sword of hepatic fibrosis.

Precision-cut liver slices as a new model to study toxicity-induced hepatic stellate cell activation in a physiologic milieu.

A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk.

Prevention of rat hepatocarcinogenesis by acyclic retinoid is accompanied by reduction in emergence of both TGF-alpha-expressing oval-like cells and activated hepatic stellate cells.

Krüppel-like factor-6 promotes preadipocyte differentiation through histone deacetylase 3-dependent repression of DLK1.

Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread.

Sex steroids have differential effects on growth and gene expression in primary human prostatic epithelial cell cultures derived from the peripheral versus transition zones.

BMP-7 opposes TGF-beta1-mediated collagen induction in mouse pulmonary myofibroblasts through Id2.

Enhanced oral tolerance in transgenic mice with hepatocyte secretion of IL-10.

Regulation of Kruppel-like factor 6 tumor suppressor activity by acetylation.

Developmental regulation of yolk sac hematopoiesis by Kruppel-like factor 6.

Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications.

Reversal of hepatic fibrosis -- fact or fantasy?

Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo.

Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC.

Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination.

Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis.

Stellate cell apoptosis by a soluble mediator from immortalized human hepatocytes.

Targeted and regulable expression of transgenes in hepatic stellate cells and myofibroblasts in culture and in vivo using an adenoviral Cre/loxP system to antagonise hepatic fibrosis.

Transcriptional regulation of stellate cell activation.

Beneficial effect of glatiramer acetate (Copaxone) on immune modulation of experimental hepatic fibrosis.

Molecular diagnosis of chronic liver disease and hepatocellular carcinoma: the potential of gene expression profiling.

A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis.

Reefer madness? Assessing the effects of cannabinoids with a less jaundiced eye.

KLF6 degradation after apoptotic DNA damage.

Adenovirus-mediated expression of BMP-7 suppresses the development of liver fibrosis in rats.

Diagnosis of hepatic fibrosis in patients with chronic hepatitis C.

Hepatic fibrosis 2006: report of the Third AASLD Single Topic Conference.

Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation.

Genomics and signaling pathways in hepatocellular carcinoma.

Reversibility of hepatic fibrosis and cirrhosis--is it all hype?

Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma.

Immunopathogenesis of hepatitis C virus infection and hepatic fibrosis: New insights into antifibrotic therapy in chronic hepatitis C.

KLF6 allelic loss is associated with tumor recurrence and markedly decreased survival in head and neck squamous cell carcinoma.

Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats.

Hepatic fibrogenesis.

A deer in the headlights: BAMBI meets liver fibrosis.

Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats.

Liver fibrosis: from mechanisms to treatment.

Insulin-like growth factor-i regulates Kruppel-like factor-6 gene expression in a p53-dependent manner.

Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver.

Experimental models of hepatocellular carcinoma.

Cannabinoids provoke alcoholic steatosis through a conspiracy of neighbors.

Targeting siRNA to arrest fibrosis.

The movement of aquatic mercury through terrestrial food webs.

Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma.

Mechanisms of hepatic fibrogenesis.

The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease.

KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis.

Hepatic fibrosis -- overview.

Future trends in hepatology: challenges and opportunities.

Increased alternative splicing of the KLF6 tumour suppressor gene correlates with prognosis and tumour grade in patients with pancreatic cancer.

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

Activation of hepatic stellate cells after phagocytosis of lymphocytes: A novel pathway of fibrogenesis.

p38-MAPK- and caspase-3-mediated superoxide-induced apoptosis of rat hepatic stellate cells: reversal by retinoic acid.

Gene expression in fixed tissues and outcome in hepatocellular carcinoma.

Pivotal role of mTOR signaling in hepatocellular carcinoma.

Preface. Hepatic fibrosis: pathogenesis, diagnosis, and emerging therapies.

TGF-beta regulates the expression of transcription factor KLF6 and its splice variants and promotes co-operative transactivation of common target genes through a Smad3-Sp1-KLF6 interaction.

Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses.

Advances in antifibrotic therapy.

Commentary: Gastroenterology and hepatology: an evolving marriage, not an imminent divorce.

Functional role of the KLF6 tumour suppressor gene in gastric cancer.

PTK787/ZK22258 attenuates stellate cell activation and hepatic fibrosis in vivo by inhibiting VEGF signaling.

Detection of novel biomarkers of liver cirrhosis by proteomic analysis.

Resveratrol amplifies profibrogenic effects of free fatty acids on human hepatic stellate cells.

Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans.

Hepatic fibrosis.

Detection of intracellular ADAMTS13, a secreted zinc-metalloprotease, via flow cytometry.

Multiple variants in toll-like receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infection.

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.

Therapeutic targeting of the PDGF and TGF-beta-signaling pathways in hepatic stellate cells by PTK787/ZK22258.

Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma.

Kupffer cell activation by ambient air particulate matter exposure may exacerbate non-alcoholic fatty liver disease.

A DDX5 S480A polymorphism is associated with increased transcription of fibrogenic genes in hepatic stellate cells.

Tumor suppressor activity of KLF6 mediated by downregulation of the PTTG1 oncogene.

Downregulation of hepatic stellate cell activation by retinol and palmitate mediated by adipose differentiation-related protein (ADRP).

Obesity, inflammatory signaling, and hepatocellular carcinoma-an enlarging link.

Klf6/copeb is required for hepatic outgrowth in zebrafish and for hepatocyte specification in mouse ES cells.

Loss of matrix metalloproteinase-2 amplifies murine toxin-induced liver fibrosis by upregulating collagen I expression.

Evolving challenges in hepatic fibrosis.

Characterization of the human Activin-A receptor type II-like kinase 1 (ACVRL1) promoter and its regulation by Sp1.

KLF6 Gene and early melanoma development in a collagen I-rich extracellular environment.

Acute liver failure is associated with elevated liver stiffness and hepatic stellate cell activation.

Reduced nicotinamide adenine dinucleotide phosphate oxidase 2 plays a key role in stellate cell activation and liver fibrogenesis in vivo.

Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis.

E3 ubiquitin ligase synoviolin is involved in liver fibrogenesis.

Pathogenesis of liver fibrosis.

Fibrosis in the liver: acute protection and chronic disease.

Platelets arrive at the scene of fibrosis……studies.

Focus.

Inhibition of PDGF, TGF-β, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib.

Dendritic cells in alcoholic liver injury and fibrosis.

Impaired dermal wound healing in discoidin domain receptor 2-deficient mice associated with defective extracellular matrix remodeling.

SPARC downregulation attenuates the profibrogenic response of hepatic stellate cells induced by TGF-β1 and PDGF.

Reactive oxygen species and NADPH oxidase 4 induced by transforming growth factor β1 are the therapeutic targets of polyenylphosphatidylcholine in the suppression of human hepatic stellate cell activation.

MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

Mechanisms of liver fibrosis associated with experimental Fasciola hepatica infection: roles of Fas2 proteinase and hepatic stellate cell activation.

Focus.

Mechanisms of hepatic fibrogenesis.

Scraping fibrosis: expressway to the core of fibrosis.

Carcinogen-induced hepatic tumors in KLF6+/- mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation.

[Polymorphism of ornithine decarboxylase antizyme inhibitor 1 gene is associated with liver cirrhosis in Chinese hepatitis B patients].

Focus.

Gene-expression signature of vascular invasion in hepatocellular carcinoma.

Nature, natural and NAFLD.

A polymorphism that delays fibrosis in hepatitis C promotes alternative splicing of AZIN1, reducing fibrogenesis.

Dendritic cell regulation of carbon tetrachloride-induced murine liver fibrosis regression.

Focus.

Human hepatic stellate cell line (LX-2) exhibits characteristics of bone marrow-derived mesenchymal stem cells.

Loss of discoidin domain receptor 2 promotes hepatic fibrosis after chronic carbon tetrachloride through altered paracrine interactions between hepatic stellate cells and liver-associated macrophages.

Current status of novel antifibrotic therapies in patients with chronic liver disease.

Discoidin domain receptor 2 deficiency predisposes hepatic tissue to colon carcinoma metastasis.

Focus. An emerging conceptual scaffold for NASH.

Glucokinase links Krüppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease.

Genomics and proteomics in liver fibrosis and cirrhosis.

Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues.

A silent partner no longer – sinusoidal endothelial cells in liver homeostasis and disease.

Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.

Fibrosis-dependent mechanisms of hepatocarcinogenesis.

Anti-fibrotic activity and enhanced interleukin-6 production by hepatic stellate cells in response to imatinib mesylate.

Focus. Metchnikoff, macrophages and the metabolic syndrome.

Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing.

CD11b(+) Gr1(+) bone marrow cells ameliorate liver fibrosis by producing interleukin-10 in mice.

Autophagy fuels tissue fibrogenesis.

Focus.

The role of chemokines in acute liver injury.

Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.

High mobility group box 1 activates Toll like receptor 4 signaling in hepatic stellate cells.

Hepatocyte growth factor enhances alternative splicing of the Kruppel-like factor 6 (KLF6) tumor suppressor to promote growth through SRSF1.

Antifibrotic activity of sorafenib in experimental hepatic fibrosis: refinement of inhibitory targets, dosing, and window of efficacy in vivo.

Focus.

Protect thee from the sins of thy fathers?

A novel murine model to deplete hepatic stellate cells uncovers their role in amplifying liver damage in mice.

Reduced hepatic stellate cell expression of Kruppel-like factor 6 tumor suppressor isoforms amplifies fibrosis during acute and chronic rodent liver injury.

Vascular injury triggers Krüppel-like factor 6 mobilization and cooperation with specificity protein 1 to promote endothelial activation through upregulation of the activin receptor-like kinase 1 gene.

Focus.

The expression patterns and clinical significance of microRNAs in liver diseases and hepatocellular carcinoma.

Autophagy and mesenchymal cell fibrogenesis.

Focus.

Cellular basis of hepatic fibrosis and its role in inflammation and cancer.

A histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor-β and vascular endothelial growth factor signalling.

Liver fibrosis in 2012: Convergent pathways that cause hepatic fibrosis in NASH.

Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis.

Therapy for fibrotic diseases: nearing the starting line.

Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma.

Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis.

Hepatitis Outreach Network: a practical strategy for hepatitis screening with linkage to care in foreign-born communities.

Post-transcriptional activation of PPAR alpha by KLF6 in hepatic steatosis.

Focus.

Endoplasmic reticulum stress induces fibrogenic activity in hepatic stellate cells through autophagy.

Preface to BBA issue devoted to fibrosis.

Focus.

Focus.

Functions of autophagy in normal and diseased liver.

CXCL12 induces hepatic stellate cell contraction through a calcium-independent pathway.

Genome-wide Transcriptome Analysis Identifies Novel Gene Signatures Implicated in Human Chronic Liver Disease.

A candidate gene study for the association of host single nucleotide polymorphisms with liver cirrhosis risk in chinese hepatitis B patients.

Focus.

β-Catenin signaling in hepatocellular cancer: Implications in inflammation, fibrosis, and proliferation.

Genetic characteristics of the human hepatic stellate cell line LX-2.

Focus.

Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease.

Hepatic stellate cells and liver fibrosis.

Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer.

"There are decades where nothing happens; and there are weeks where decades happen"--Vladimir Ilyich Lenin.

Replacing a crystal ball with a calculator in predicting liver disease outcomes.

Central role of conventional dendritic cells in regulation of bone marrow release and survival of neutrophils.

Transporting pharmacogenomics into clinical practice.

Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C?

Association of genetic variants with rapid fibrosis: progression after liver transplantation for hepatitis C.

Hepatic fibrosis and the microenvironment: fertile soil for hepatocellular carcinoma development.

NRBF2 regulates autophagy and prevents liver injury by modulating Atg14L-linked phosphatidylinositol-3 kinase III activity.

LAP degradation product reflects plasma kallikrein-dependent TGF-β activation in patients with hepatic fibrosis.

Tracking HCC pathogenesis but not the tumor cells after biopsy.

A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration.

Final and future frontiers.

Inhibition of the CXCL12/CXCR4 chemokine axis with AMD3100, a CXCR4 small molecule inhibitor, worsens murine hepatic injury.

Focusing on the past, present, and future of hepatology.

IL-17A enhances the expression of profibrotic genes through upregulation of the TGF-β receptor on hepatic stellate cells in a JNK-dependent manner.

The past 10 years of gastroenterology and hepatology-reflections and predictions.

Alcohol and inflammatory responses: summary of the 2013 Alcohol and Immunology Research Interest Group (AIRIG) meeting.

Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop.

Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014.

Principles on the path to a hepatologist's enlightenment.

β-PDGF receptor expressed by hepatic stellate cells regulates fibrosis in murine liver injury, but not carcinogenesis.

Pathobiology of liver fibrosis: a translational success story.

Epithelial Xbp1 is required for cellular proliferation and differentiation during mammary gland development.

Preserved Expression of mRNA Coding von Willebrand Factor-Cleaving Protease ADAMTS13 by Selenite and Activated Protein C.

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.

Hepatic fibrosis: Concept to treatment.

Granulocyte macrophage colony-stimulating factor is required for aortic dissection/intramural haematoma.

Emerging and disease-specific mechanisms of hepatic stellate cell activation.

Modulation of cardiac fibrosis by Krüppel-like factor 6 through transcriptional control of thrombospondin 4 in cardiomyocytes.

A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection.

Hepatic Fibrosis: Emerging Therapies.

Induction and contribution of beta platelet-derived growth factor signalling by hepatic stellate cells to liver regeneration after partial hepatectomy in mice.

L(59) TGF-β LAP degradation products serve as a promising blood biomarker for liver fibrogenesis in mice.